A High-throughput Screening of a Chemical Compound Library in Ovarian Cancer Stem Cells

BACKGROUND

Epithelial ovarian cancer has a poor prognosis, mostly due to its late diagnosis and the development of drug resistance after a first platinum-based regimen. The presence of a specific population of "cancer stem cells" could be responsible of the relapse of the tumor and the development of resistance to therapy. For this reason, it would be important to specifically target this subpopulation of tumor cells in order to increase the response to therapy.

METHOD

We screened a chemical compound library assembled during the COST CM1106 action to search for compound classes active in targeting ovarian stem cells. We here report the results of the high-throughput screening assay in two ovarian cancer stem cells and the differentiated cells derived from them.

RESULTS AND CONCLUSION

Interestingly, there were compounds active only on stem cells, only on differentiated cells, and compounds active on both cell populations. Even if these data need to be validated in ad hoc dose response cytotoxic experiments, the ongoing analysis of the compound structures will open up to mechanistic drug studies to select compounds able to improve the prognosis of ovarian cancer patients.

Cytokine profile, HLA restriction and TCR sequence analysis of human CD4+ T clones specific for an immunodominant epitope of Mycobacterium tuberculosis 16-kDa protein

The identification of immunodominant and universal mycobacterial peptides could be applied to vaccine design and have an employment as diagnostic reagents. In this paper we have investigated the fine specificity, clonal composition and HLA class II restriction of CD4+ T cell clones specific for an immunodominant epitope spanning amino acids 91-110 of the 16-kDa protein of Mycobacterium tuberculosis. Twenty-one of the tested 28 clones had a Th1 profile, while seven clones had a Th0 profile. None of the clones had a Th2 profile. While the TCR AV gene usage of the clones was heterogeneous, a dominant TCR BV2 gene family was used by 18 of the 28 clones. The CDR3 regions of BV2+ T cell clones showed variation in lengths, but a putative common motif R-L/V-G/S-Y/W-E/D was detected in 13 of the 18 clones. Moreover, the last two to three residues of the putative CDR3 loops, encoded by conserved BJ sequences, could also play a role in peptide recognition. Antibody blockade and fine restriction analysis using HLA-DR homozygous antigen-presenting cells established that 16 of 18 BV2+ peptide-specific clones were DR restricted and two clones were DR-DQ and DR-DP restricted. Additionally, five of the 18 TCRBV2+ clones recognized peptide 91-110 in association with both parental and diverse HLA-DR molecules, indicating their promiscuous recognition pattern. The ability of peptide 91-110 to bind a wide range of HLA-DR molecules, and to stimulate a Th1-type interferon (IFN)-gamma response more readily, encourage the use of this peptide as a subunit vaccine component.

Synthesis, solution conformation and interleukin-6-related activities of interleukin-6 peptides

Interleukin-6 (IL-6) is a member of the cytokine superfamily characterised by a wide variety of biological activities on various cell types. IL-6 exerts pleiotropic activities on hematopoiesis in the immune response and it is the main regulator of acute-phase protein synthesis in liver cells. According to structure-function studies, residues of helix A located at the N-terminal part and/or helix D of the C-terminal part of the protein are involved in the induction of acute-phase responses. Two groups of synthetic peptides corresponding to the 18-46 N-terminal and the 168-185 C-terminal regions of the IL-6 were prepared by solid-phase synthesis to identify structural requirements for induction of fibrinogen or complement factor B synthesis. These peptides were characterised by amino acid analysis, analytical reversed-phase high-performance liquid chromatography, fast atom bombardment mass spectrometry, and circular dichroism (CD) spectroscopy. CD results showed that under appropriate conditions both 18-46 and 168-185 related peptides are able to adopt markedly ordered conformation. We demonstrated that even octapeptides from the N-terminal part and truncated derivatives of the C-terminal region preserved some tendency to display the CD curve of periodic conformation. The ability of the peptides to induce de novo synthesis of acute-phase proteins was evaluated by measuring fibrinogen and complement factor B levels in the supernatants of human HepG2 cells. These results showed that residues 21-34 are critical for eliciting fibrinogen synthesis in the presence or absence of IL-6. In contrast, the full-length 168-185 peptide is required for the induction of complement factor B response.